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Key Points
•CXCR4 antagonist
AMD3100 but not
KRH3955 reverses the
CXCL12 chemokine
gradient across the
bone marrow
endothelium.
•CXCR4 antagonists
mobilize stem cells from
the bone marrow by
distinct mechanisms.
Pharmacological mobilization of hematopoietic progenitor cells (HPCs) is used clinically to
harvest HPCs for bone marrow transplants. It is now widely accepted that the CXCR4:
CXCL12 chemokine axis plays a critical role in the retention of HPCs in the bone marrow,
and CXCR4 antagonists have been developed for their mobilization. The ﬁrst of this class of
drugs to be US Food and Drug Administration-approved was the bicyclam AMD3100. In
addition to mobilizing HPCs and leukocytes in na¨ıve mice, AMD3100 has been shown to
mobilize mesenchymal progenitor cells (MPCs) in vascular endothelial growth factor
(VEGF-A) pretreated mice. AMD3100 binds to the transmembrane region of CXCR4 and is
thought to mobilize HPCs by reversing the gradient of CXCL12 across the bone marrow
endothelium. Consistent with this hypothesis, our data show that selective neutralization
of CXCL12, with chalcone 4-phosphate (C4P), inhibited AMD3100-stimulated mobilization
of HPCs and leukocytes in na¨ıve mice and MPCs in VEGF-A pretreated mice. In contrast it
is shown here that the CXCR4 antagonist KRH3955 that binds to the extracellular loop of
CXCR4 does not reverse the CXCL12 chemokine gradient. However, this drug eﬃciently
mobilizes HPCs, a response that is not inhibited by C4P. In contrast, KRH3955 does not
mobilize MPCs in VEGF-A pretreated mice. These data suggest that CXCR4 antagonists that
bind to distinct regions of the receptor mobilize progenitor cells by distinct molecular
mechanisms.
Introduction
Chemokine receptors are critical for directed migration of leukocytes from the circulation to sites of
inflammation.1 In addition, a number of chemokines play important roles in tissue homeostasis. One
such chemokine is CXCL12 (C-X-C motif chemokine ligand 12), a chemokine produced constitutively
in the bone marrow, which through binding to CXCR4 (C-X-C chemokine receptor type 4) expressed
by leukocytes and hematopoietic stem/progenitor cells (HSPCs) plays a critical role in the retention
and homing of these cells to the bone marrow.2-9 The small organic bicyclam molecule Plerixafor
(AMD3100) is a CXCR4 antagonist that was originally developed as an anti-HIV agent and was shown
to inhibit viral replication of the X4 HIV strain known to require CXCR4 for entry into T cells.10
However, during preclinical and phase I clinical studies, it was reported that administration of
AMD3100 in mice and humans resulted in a rapid rise in circulating leukocytes and HSPCs within a
matter of hours.11-13
Granulocyte colony-stimulating factor (G-CSF) is used clinically to mobilize HSPCs for bone marrow
transplants (BMTs). Optimal mobilization requires daily administration of G-CSF over 4 to 6 days.
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In terms of its mechanism of action, G-CSF is thought to disrupt the
CXCR4:CXCL12 chemokine retention axis by reducing local
messenger RNA and protein levels of CXCL12.2,3,5,14 In approx-
imately 20% of donors, the so-called poor mobilizers, G-CSF does
not mobilize sufficient HSPCs to perform a BMT. AMD3100 was
shown to act synergistically with G-CSF with respect to HSPC
mobilization, and this led to AMD3100 being approved by the US
Food and Drug Administration for clinical use in combination with
G-CSF for poor mobilizers.13,15,16
Although it was originally thought that AMD3100 mobilized HSPCs
as a result of direct disruption of the CXCR4:CXCL12 retention
axis, through antagonism of CXCR4, a recent study reported that
there was a rapid elevation of CXCL12 in the peripheral circulation
of mice following AMD3100 administration, thereby reversing the
gradient of CXCL12 across the bone marrow endothelium.13,17 The
authors provided evidence that AMD3100 stimulated the trans-
location of CXCL12 across the bone marrow sinusoidal endothe-
lium into the blood and that the chemokine gradient that was
generated was critical in driving HSPC mobilization.17 These data
have not as yet been corroborated by others.
In addition to hematopoietic progenitor cells (HPCs), AMD3100
has been reported to mobilize endothelial progenitor cells (EPCs)
and mesenchymal progenitor cells (MPCs) from the bone
marrow.18,19 Unlike EPCs and HPCs, in which AMD3100 alone
was sufficient for mobilization, combination treatment with vascular
endothelial growth factor (VEGF-A) was required for the mobiliza-
tion of MPCs.18 It is currently not known how this combination
treatment stimulates MPC mobilization.
In this article we have investigated the mobilization of HPCs
and MPCs by AMD3100 and a chemically distinct CXCR4
antagonist, KRH3955.20,21 KRH3955 is reported to have a higher
affinity for CXCR4 and a distinct target site to AMD3100.21 As
with AMD3100, preliminary studies investigating the anti-HIV
activity of KRH3955 showed that a single dose of this drug
elevated leukocyte counts in peripheral blood.22 Here, we have
made use of a specific CXCL12 neutraligand, chalcone 4-
phosphate,23,24 to address the question of whether an elevation
of CXCL12 in the plasma is required for mobilization of HPCs and
MPCs by these distinct CXCR4 antagonists.
Our data corroborate the previous report that AMD3100
stimulates a reversal of the CXCL12 chemokine gradient across
the bone marrow sinusoidal endothelium and moreover that an
elevation in circulating CXCL12 is necessary for AMD3100-
stimulated mobilization of leukocytes and HPCs into the blood.
Furthermore, we demonstrate that this mechanism also underlies
the mobilization of MPCs by AMD3100 in combination with
VEGF-A. In contrast, KRH3955 does not elevate circulating
concentrations of CXCL12, but it does mobilize HPCs and
leukocytes, suggesting a distinct mechanism of action to
AMD3100. Unexpectedly, KRH3955 in combination with
VEGF-A failed to mobilize MPCs, suggesting that the reversed
CXCL12 gradient is critical for their mobilization.
Methods
Mice
BALB/c female mice purchased from Harlan Laboratories were
used throughout this study, which were between the ages of 8 and
12 weeks and weighing 18 to 22 g. Mice were age- and weight-
matched for each experiment. All studies were carried out under the
United Kingdom’s Animals (Scientific Procedures) Act of 1986 and
local ethical approval from Imperial College London.
Administration of drugs
Mice were administered AMD3100 (5 mg/kg intraperitonially [IP];
Sigma) or vehicle (phosphate-buffered saline [PBS]) 1 hour prior to
the cull (unless stated otherwise in time-course experiments). Mice
were administered KRH3955 (30 mg/kg by oral gavage; Kureha
Corporation) or vehicle (water) 2 h prior to the cull (unless stated
otherwise in time-course experiments). The CXCL12 neutraligand
chalcone 4-phosphate (1.5 mmol/kg IV; Laboratoire d’Innovation
The´rapeutique) or vehicle (PBS) was administered 60 min prior to
the injection of AMD3100, KRH3955, or vehicle. Cytokine pre-
treatment of VEGF-A (100 mg/kg IP; PeproTech) or vehicle (PBS)
was administered once daily for 4 days. Twenty-four hours after the
last injection, mice were administered CXCR4 antagonist, as is
stated above.
Cell isolation and colony assays
Peripheral blood was collected via cardiac puncture using a
syringe precoated with and containing sodium citrate (100 mL;
Sigma). Once the total volume was recorded, citrated blood was
centrifuged to collect blood plasma when required. The remaining
soft pellet containing cells was red blood cell-lysed, and to
enumerate HPCs (colony-forming unit [CFU] HPCs), we added
1 3 105 cells to tissue culture-treated petri dishes containing
1 mL of Methocult (M3434; StemCell Technologies). Cultures
were incubated at 37°C, 5% CO2, and quantified on day 12. To
enumerate MPCs (CFU-Fs), we added 1 3 106 cells to tissue
culture-treated 6-well plates containing 3 mL of Mesencult
(05502; StemCell Technologies). Cultures were incubated at
37°C, 5% CO2, and medium was changed on day 7. CFU-Fs were
quantified on day 21.
Harvest of bone marrow cells and supernatant
Femurs were harvested from mouse hind limbs. Bones were
cleaned and kept on ice, before bone marrow cells were collected
by bone marrow flush using a syringe containing D20 (Dulbecco’s
modified Eagle medium supplemented with 20% fetal calf serum).
For collection of bone marrow supernatant, bone marrow was
flushed out with 0.5 mL of cold PBS per femur. Bone marrow cells
were resuspended and centrifuged, and the cell-free supernatant
was collected.
Flow cytometry analysis
Flow cytometry was used to determine the surface expression of
CXCR4 on bone marrow-derived MPCs, HPCs, and endothelial
cells. Cells were stained with fluorophore-conjugated monoclonal
antibodies directed against CD45, CD31, platelet-derived growth
factor receptor (PDGFR)-a, SCA-1, cKit, Lineage panel (cock-
tail), and CXCR4. Cells were acquired using a Fortessa flow
cytometer (Becton Dickson). Data were analyzed using FlowJo
software (version 7.6.5). Fluorescence minus one (FMO) controls
were used to set gates appropriately for analysis. The mean
fluorescence intensity was calculated using relevant control data
(FMOs). Commercial antibodies (clones, fluorophores, and sources)
are listed in supplemental Table 1.
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CXCL12 enzyme-linked immunosorbent assay
CXCL12 content in bone marrow (BM) supernatant and peripheral
blood (PB) plasma was quantified using paired antibodies
(MAB350 and BAF351; RnD systems), and the assay was
performed according to the manufacturer’s instructions. Recombi-
nant mouse CXCL12 (RnD systems) was used to create a standard
curve.
Data analysis and statistics
Data analysis was performed in GraphPad Prism 5 (GraphPad
Software, La Jolla, CA). Data are expressed as the mean and
standard error of the mean (mean 6 SEM), and statistical
analysis was performed using one-way analysis of variance
(ANOVA) with Dunnett or Bonferroni multiple comparison
test, where appropriate. Results were considered statistically
significant when P , .05 and are represented using asterisks
(*P, .05; **P, .01; ***P, .001); n5 number of mice per group.
For further details on the number of mice per group, see
supplemental Table 2.
Results
Bone marrow mesenchymal and hematopoietic
progenitor cells and endothelial cells express high
levels of CXCR4 on the cell surface
Previous research demonstrating expression of CXCR4 on MPCs
was carried out on culture-expanded cells. Despite the fact that it is
widely accepted that CXCL12 is important in directing injected
MPCs to the site of injury/disease in vivo, results on surface
expression of the receptor are inconsistent.25-29 In particular,
several studies indicate that culture expansion of MPCs results
to downregulated expression of CXCR4.25,29,30 Here, surface
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Figure 1. CXCR4 surface expression on bone marrow cell populations. Bone marrow cells were collected from mice by bone marrow flush for analysis of CXCR4
expression by flow cytometry. (A) Cells were stained with antibodies to detect mesenchymal progenitor cells (PaS; TER1192CD452CD312PDGFRa1SCA11), hematopoietic
progenitor cells (LSK; Lin2cKit1SCA11), and BMECs (Lin2CD452CD311). Histograms of surface CXCR4 expression on cells (solid red areas) were determined by flow
cytometry. Open dashed-line histograms represent FMO controls. CXCR4 positive percentage of cells within each population (B) and calculated mean fluorescence intensity
for CXCR4 (C) (n 5 4 mice per group). Data from 2 independent experiments are represented as mean 6 SEM. MFI, mean fluorescence intensity.
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expression of CXCR4 was investigated on freshly isolated murine
MPCs (PaS), HPCs (LSK), and BM endothelial cells (BMECs)
(Figure 1A). MPCs expressed high levels of surface CXCR4, with
levels comparable to HPCs and BMECs (Figure 1A-C).
AMD3100 induces a transient reversal of the bone
marrow:blood CXCL12 chemokine gradient
mediating rapid mobilization of leukocytes and
hematopoietic progenitor cells
Single IP treatment of mice with AMD3100 (5 mg/kg) induced
mobilization of leukocytes and HPCs, with peak numbers in
the circulation after 1 hour. The number of circulating leukocytes
returned to baseline after 4 hours (Figure 2A-B). Peak mobiliza-
tion coincided with maximum changes in CXCL12 levels de-
tected in the blood and bone marrow, with a significant decrease
in the bone marrow and an increase in the blood, at 1h, returning
to baseline by 4 hours (Figure 2C-D). These observations are
consistent with the proposal that a rapid, but transient, reversal of
the bone marrow:blood CXCL12 chemokine gradient mediates
mobilization of leukocytes and HPCs into the blood following
AMD3100 treatment.17
Neutralization of CXCL12 suppresses mobilization of
leukocytes and hematopoietic progenitor cells
by AMD3100
Chalcone 4-phosphate (C4P) is a novel and highly soluble analog
of chalcone 4. The compound is a prodrug; after in vivo cleavage
of the phosphate group, it converts into the active chalcone 4
molecule that selectively binds CXCL12 and neutralizes its func-
tion.24 Chalcone 4 was shown to prevent induction of CXCR4
signaling and CXCL12-mediated CXCR4 internalization in vitro.23
To investigate whether elevated levels of circulating CXCL12 were
required for mobilization of leukocytes and HPCs by AMD3100, we
administered C4P IV (1.5 mmol/kg) to neutralize CXCL12 in the
peripheral circulation. C4P treatment significantly reduced the
number of circulating leukocytes and HPCs mobilized by AMD3100
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Figure 2. AMD3100-induced changes in CXCL12 gradient
coincided with and mediated mobilization of leukocytes
and HPCs. (A-D) Mice were administered AMD3100 (5 mg/kg
mouse IP) or vehicle (dash), and at varying time points (1, 2, and
4 hours), blood was collected for analysis of circulating total
nucleated cells (TNCs) (A) and CFU-HPCs (B) (n 5 11-14 mice
per group). Femoral bone marrow and peripheral blood were
collected for quantification of CXCL12 in bone marrow (BM)
supernatant (C) and PB plasma (D), respectively (n 5 7-14 mice
per group). CXCL12 levels are shown as picograms per milliliter.
Data of at least 3 independent experiments are represented as
mean 6 SEM. *P , .05; **P , .01; ***P , .001 (one-way
ANOVA with Dunnett test). (E-F) Mice were administered
AMD3100 or vehicle (dash) in the presence or absence of the
CXCL12 neutraligand chalcone 4-phosphate (C4P; 1.5 mmol/kg
mouse IV), and 1 hour later, blood was collected for analysis of
circulating TNCs (E) and CFU-HPCs (F) (n 5 5-10 mice per
group). TNCs and CFU-HPCs are shown as cells and colonies
per milliliter of blood, respectively. Data from at least 2 in-
dependent experiments are represented as mean 6 SEM.
**P , .01; ***P , .001 (one-way ANOVA with Bonferroni test).
NL, neutraligand; ns, not significant.
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(Figure 2E-F). These data suggest that the reversal of the bone
marrow:blood CXCL12 gradient is required for the mobilization of
leukocytes and HPCs by AMD3100.
Neutralization of CXCL12 abrogates pharmacological
mobilization of mesenchymal progenitor cells
Pitchford et al demonstrated in 2009 that administration of
AMD3100 was required to achieve MPC mobilization in mice
pretreated with VEGF-A.18 It was therefore of interest to investigate
whether mobilization of MPCs by AMD3100 was similarly de-
pendent on changes in the CXCL12 chemokine gradient. Mea-
surement of CXCL12 in blood and BM showed that in mice
pretreated with VEGF-A over 4 days, AMD3100 stimulated the
reversal of the CXCL12 chemokine gradient to the same extent as
in mice treated with vehicle alone (Figure 3A-B). We show here that
C4P treatment abolished mobilization of MPCs in mice receiving
VEGF-A (100 mg/kg) and AMD3100 in combination (Figure 3C).
This finding suggests that reversal of the CXCL12 chemokine
gradient is an essential step for MPC mobilization by VEGF-A in
combination with AMD3100.
KRH3955 rapidly mobilizes leukocytes and
hematopoietic progenitor cells in the absence of a
robust CXCL12 chemokine gradient
Previous work in monkeys demonstrated that a single dose of
KRH3955 mobilizes leukocytes into peripheral blood.22 Our results
show that a single administration of KRH3955 (30 mg/kg) induced
mobilization of leukocytes and HPCs in mice, with largely elevated
numbers in the circulation after 2 h. The number of circulating
cells returned to baseline by 24 hours (Figure 4A-B). Peak
mobilization coincided with a significant decrease in CXCL12
levels in the BM, but no changes were detected in the plasma
levels of CXCL12 (Figure 4C-D). These findings indicate that
KRH3955 does not stimulate the dramatic reversal of the bone
marrow:blood CXCL12 chemokine gradient as is seen with
AMD3100.
KRH3955-induced mobilization of leukocytes and
hematopoietic progenitor cells is not mediated by an
active CXCL12 chemokine gradient
No changes were detected in the number of circulating leukocytes
and HPCs mobilized by KRH3955, when C4P was administered to
mice (Figure 4E-F). These data indicate that KRH3955-stimulated
mobilization of leukocytes and HPCs is not dependent on a
CXCL12 chemokine gradient across the BM endothelium.
KRH3955 inhibits AMD3100-mediated elevation of
blood CXCL12
The 2 CXCR4 antagonists were administered in combination to see
whether they demonstrated drug interaction in the context of
mobilization. Treatment was delivered using optimal mobilization
conditions that were previously determined for each drug. As is
indicated in Figure 5A-B, no changes were detected in the number
of mobilized leukocytes and HPCs following combination of
KRH3955 and AMD3100, in comparison with either drug alone.
The increase in circulating CXCL12 stimulated by AMD3100 alone
was significantly reduced when AMD3100 was administered in
combination with KRH3955 (Figure 5C).
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Figure 3. Neutralization of the CXCL12 chemokine gradient in VEGF-A pretreated
mice. (A-B) Mice were pretreated with VEGF-A (VA; 100 mg/kg mouse IP) or vehicle (dash)
once daily on 4 consecutive days. Twenty-four hours after the last injection, mice were
administered AMD3100, and 1 hour later, mice were sacrificed. Femoral bone marrow and
peripheral blood were collected for quantification of CXCL12 in BM supernatant (A) and PB
plasma (B), respectively (n 5 6-15 mice per group). CXCL12 levels are shown as picograms
per milliliter. (C) Mice were pretreated with VEGF-A or vehicle (dash) once daily on 4
consecutive days. Twenty-four hours after the last injection, mice were administered AMD3100
or vehicle (dash) in the presence or absence of C4P, and 1 hour later, blood was collected
for analysis of circulating CFU-Fs (n5 6-10 mice per group). CFU-Fs are shown as colonies
per milliter of blood. Data from at least 2 independent experiments are represented as mean6
SEM. *P, .05; **P, .01; ***P, .001 (one-way ANOVA with Bonferroni test). VA, VEGF-A.
1938 REDPATH et al 10 OCTOBER 2017 x VOLUME 1, NUMBER 22
KRH3955 fails to mobilize mesenchymal progenitor
cells in VEGF-A pretreated mice
We next assessed whether KRH3955, which fails to generate a
robust reversal of the CXCL12 chemokine gradient (Figures 4C-D
and 6A) was able to mobilize MPCs. Indeed, treatment with
KRH3955 did not stimulate mobilization of MPCs in VEGF-A
pretreated mice (Figure 6B). This indicates the importance of the
CXCL12 gradient reversal in MPC mobilization.
Discussion
HPCs may be mobilized in response to blood-borne chemokines
that form a chemotactic gradient across the BM sinusoidal
endothelium. Thus CCL11, CXCL8, and CXCL2 all induce a rapid
mobilization of HPCs when injected into animals.31-33 The chemo-
kine CXCL12 is produced constitutively in the BM, and there is now
an extensive literature that is consistent with the notion that the
CXCR4:CXCL12 chemokine axis is critical for HPC retention in the
BM.34 Thus, for example, circadian variations in levels of CXCL12 in
the BM have been shown to correlate with retention and egress of
HPCs,35 and sustained overexpression of CXCL12 using an
adenovirus and other drugs that are CXCR4 agonists have been
shown to mobilize HPCs into the blood.36-38 CXCL12 is produced
locally in damaged tissues and is reported to be critical for the
mobilization and recruitment of BM stem/progenitor cells to the site
of injury.39-45 Taken together, these studies indicate that the relative
level of CXCL12 in the blood and BM is one factor that regulates
progenitor cell retention/mobilization under homeostasis and in
disease. Understanding this mechanism of retention has led to the
development of CXCR4 antagonists as HPC-mobilizing drugs.
The BM endothelium expresses CXCR4, and complexes of
CXCR4:CXCL12 have been reported to translocate CXCL12
across the BM endothelium in both directions.17,46 In one paper it
has been reported that the CXCR4 antagonist AMD3100 enhances
the translocation of CXCL12 across the BM endothelium into the
blood, and indeed it has been suggested that this drug mobilizes
HPCs by virtue of its ability to reverse the CXCL12 chemokine
gradient.17 In this article, we have compared the ability of AMD3100
and a distinct CXCR4 antagonist, KRH3955, to mobilize leukocytes,
HPCs, and MPCs into the blood and specifically investigated
whether the reversal of the CXCL12 chemokine gradient plays a
role in their ability to mobilize cells from the BM. Our results indicate
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Figure 4. Kinetics of KRH3955-induced mobilization of leuko-
cytes and HPCs and studies on the bone marrow:blood
CXCL12 chemokine gradient. (A-D) Mice were administered
KRH3955 (30 mg/kg mouse by oral gavage) or vehicle (dash), and at
varying time points (2, 6, and 24 hours), blood was collected for
analysis of circulating TNCs (A) and CFU-HPCs (B) (n 5 7-10 mice
per group). Femoral bone marrow and peripheral blood were
collected for quantification of CXCL12 in BM supernatant (C) and
PB plasma (D), respectively (n 5 7-17 mice per group). CXCL12
levels are shown as picograms per milliliter. Data from at least 2
independent experiments are represented as mean 6 SEM. ***P , .001
(one-way ANOVA with Dunnett test). (E-F) Mice were administered
KRH3955 or vehicle (dash) in the presence or absence of C4P, and 2 hours
later, blood was collected for analysis of circulating TNCs (E) and CFU-
HPCs (F) (n 5 4-8 mice per group). TNCs and CFU-HPCs are shown as
cells and colonies per milliliter of blood, respectively. Data from 2 indepen-
dent experiments are represented as mean 6 SEM.
*P , .05; **P , .01; ***P , .001 (one-way ANOVA with Bonferroni test).
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that AMD3100, but not KRH3955, stimulates a rapid rise in plasma
levels of CXCL12 coinciding with a decrease in the concentration
of CXCL12 in the bone marrow and mobilization of leukocytes and
HPCs into the blood. Moreover, use of the CXCL12 neutraligand,
C4P, confirmed that CXCL12 activity is required for AMD3100-
stimulated HPC and leukocyte mobilization. Our results are
therefore consistent with those of Dar et al, who originally
proposed (in 2011) that mobilization of HPCs by AMD3100 is an
active process.17 Furthermore, we have shown that AMD3100
stimulated mobilization of MPCs, which requires pretreatment of
mice with VEGF-A is also mediated by the same mechanism: C4P
inhibiting this response.
In contrast we have shown that the CXCR4 antagonist KRH3955
stimulates leukocyte and HPCmobilization by a distinct mechanism,
in that mobilization is not accompanied by any change in plasma
levels of CXCL12 and is not inhibited by C4P. Previous studies in
primates demonstrated that KRH3955 induces an increase in
circulating leukocytes, but we are the first to demonstrate that
KRH3955 mobilizes HPCs into the blood.22 Interestingly,
KRH3955 does not mobilize MPCs in VEGF-A pretreated mice,
suggesting that reversal of the CXCL12 chemokine gradient is
critical for mobilization of MPCs.
Comparative in vitro studies of AMD3100 and KRH3955 revealed that
KRH3955 exhibited a 100-fold lower IC50 for CXCL12 binding, a
stronger binding affinity, and a slower dissociation rate than did
AMD3100. Moreover, in functional assays, KRH3955 was a more
potent anti-HIV drug than was AMD3100.21 Analysis of the mechanism
whereby CXCL12 interacts with CXCR4 has shown that the chemokine
interacts via a 2-step process. In the first step, CXCL12 binds to the
extracellular region of CXCR4 via its b sheet and 50s loop, a step that
does not lead to receptor conformational change or activation, whereas
in the second step the interaction of the N terminus of CXCL12 with the
transmembrane helices of CXCR4 leads to a conformational change of
the receptor and activation of G-protein signaling.47 AMD3100 and
KRH3955 have been shown to interact with CXCR4 at distinct sites.
KRH3955 binds selectively to the extracellular loop of CXCR4, and
AMD3100 binds to the transmembrane region.21,47 As such, it is
predicted that KRH3955 inhibits binding of CXCL12 to both the
extracellular loop and transmembrane region of CXCR4. In contrast,
AMD3100 still permits CXCL12 binding to the extracellular loop;
thus it is possible that CXCR4:CXCL12:AMD3100 complexes are
formed. Given that higher plasma concentrations of CXCL12 are
observed in vivo following AMD3100 treatment, we propose that
the binding of AMD3100 to the transmembrane region of CXCR4
favors translocation of CXCL12 across the BM endothelium
through formation of these complexes. In contrast, KRH3955 acts
as a more traditional competitive antagonist, potentially mobilizing
HPCs and leukocytes by directly disrupting the CXCR4:CXCL12
retention system. Therefore, it appears that KRH3955 stimulates a
mechanistically distinct mobilization response in comparison with
AMD3100.
When an experiment was performed administering both AMD3100 and
KRH3955 in vivo, the extent of HPC and leukocyte mobilization was no
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Figure 5. Combination treatment of KRH3955 and AMD3100; KRH3955 hinders CXCL12 changes stimulated by AMD3100. (A-C) Mice were administered
KRH3955 or vehicle (dash), and 1 hour later, mice were further administered AMD3100 or vehicle (dash). One hour after the last injection, blood was collected for analysis of
circulating TNCs (A) and CFU-HPCs (B) (n 5 5-8 mice per group). TNCs and CFU-HPCs are shown as cells and colonies per milliliter of blood, respectively. (C) CXCL12
was quantified in PB plasma (n 5 5-7 mice per group). CXCL12 levels are shown as picograms per milliliter. Data from 2 independent experiments were represented as
mean 6 SEM. **P , .01; ***P , .001 (one-way ANOVA with Bonferroni test).
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greater than it was with either drug alone. It is possible that maximal
mobilization was achieved under these conditions. Notably, drug
interaction was evident after assessment of plasma CXCL12 changes.
KRH3955 administration significantly dampened the elevation of
circulating CXCL12 mediated by AMD3100. It is possible that binding
of KRH3955 with high affinity to the extracellular domain of CXCR4
displaces and further inhibits binding of CXCL12 (or binding of
AMD3100) to the receptor. As a result, this hinders formation of
CXCR4:CXCL12:AMD3100 complexes and thereby reduces the
translocation of CXCL12 across the BM sinusoidal endothelium into
the blood.
In conclusion, our data are consistent with the theory that
AMD3100 mediates mobilization of leukocytes, HPCs, and
MPCs via reversal of the CXCL12 chemokine gradient across
the BM endothelium. KRH3955, on the other hand, which does
not reverse the CXCL12 chemokine gradient, stimulates the
mobilization of leukocytes and HPCs but not MPCs (Figure 7).
These data suggest that generation of a CXCL12 chemokine
gradient across the BM endothelium is vital for pharmacological
mobilization of MPCs. Overall, this study indicates that CXCR4
antagonists mobilize cells from the BM by distinct mechanisms
that are dependent on their CXCR4-binding sites.
Studying the efficacy of CXCR4 antagonists to mobilize HPCs
and MPCs, and understanding the mechanism underlying this
response, is important in selecting and applying these compounds
used for stem cell mobilization. For example, designing a CXCR4
antagonist, such as AMD3100, that binds to the transmembrane
region of CXCR4 and thereby stimulates the reversal of the
CXCL12 gradient may be used to mobilize both HPCs and MPCs.
This may be advantageous in the context of BMTs, in which MPCs
are thought to improve engraftment of HPCs.48-50 In addition,
MPC mobilization may enhance tissue repair in the context of
tissue injury, such as cardiovascular disease or a musculoskeletal
injury.45,49,51-53
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